Yuanliang Yan

5.5k total citations · 2 hit papers
146 papers, 3.9k citations indexed

About

Yuanliang Yan is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yuanliang Yan has authored 146 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Molecular Biology, 54 papers in Cancer Research and 46 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yuanliang Yan's work include Ferroptosis and cancer prognosis (38 papers), RNA modifications and cancer (34 papers) and Cancer-related molecular mechanisms research (26 papers). Yuanliang Yan is often cited by papers focused on Ferroptosis and cancer prognosis (38 papers), RNA modifications and cancer (34 papers) and Cancer-related molecular mechanisms research (26 papers). Yuanliang Yan collaborates with scholars based in China, United States and Japan. Yuanliang Yan's co-authors include Zhijie Xu, Zhicheng Gong, Shuangshuang Zeng, Long Qian, Lunquan Sun, Qiuju Liang, Bi Peng, Jie Wei, Shuang Dai and Yuanhong Liu and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Yuanliang Yan

137 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exosome-based immunotherapy: a promising approach for cancer treatment

2020 397 citations Zhijie Xu, Shuangshuang Zeng et al. profile →
Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment

2023 136 citations Qiaoli Yi, Zhijie Xu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuanliang Yan China	35	2.5k	1.5k	730	567	504	146	3.9k
Gang Li China	37	3.0k 1.2×	1.7k 1.2×	392 0.5×	590 1.0×	700 1.4×	176	4.6k
Yanfang Liu China	33	2.5k 1.0×	1.3k 0.9×	527 0.7×	824 1.5×	904 1.8×	206	4.4k
Xiaobing Liu China	28	2.2k 0.9×	1.1k 0.7×	631 0.9×	869 1.5×	271 0.5×	150	4.6k
Hanwen Zhang China	37	3.2k 1.3×	2.2k 1.5×	387 0.5×	691 1.2×	662 1.3×	143	5.0k
Tong Chen China	35	3.1k 1.2×	1.4k 0.9×	433 0.6×	737 1.3×	538 1.1×	218	5.2k
Xi Yang China	33	2.1k 0.8×	1.2k 0.8×	983 1.3×	826 1.5×	321 0.6×	197	4.2k
Jing Ren China	31	1.7k 0.7×	1.1k 0.7×	420 0.6×	446 0.8×	621 1.2×	101	3.1k
Ying Han China	36	2.0k 0.8×	1.0k 0.7×	608 0.8×	951 1.7×	421 0.8×	235	4.3k
Zhao Huang China	28	2.1k 0.8×	1.2k 0.8×	505 0.7×	931 1.6×	573 1.1×	60	4.1k
Chang Zou China	33	2.1k 0.9×	1.1k 0.7×	547 0.7×	997 1.8×	499 1.0×	120	3.9k

Countries citing papers authored by Yuanliang Yan

Since Specialization

Citations

This map shows the geographic impact of Yuanliang Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanliang Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanliang Yan more than expected).

Fields of papers citing papers by Yuanliang Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuanliang Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanliang Yan. The network helps show where Yuanliang Yan may publish in the future.

Co-authorship network of co-authors of Yuanliang Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Yuanliang Yan. A scholar is included among the top collaborators of Yuanliang Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanliang Yan. Yuanliang Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yan, Yuanliang, Jun Hu, Ning Han, et al.. (2025). Sorafenib-loaded metal-organic framework nanoparticles for anti-hepatocellular carcinoma effects through synergistically potentiating ferroptosis and remodeling tumor immune microenvironment. Materials Today Bio. 32. 101848–101848. 5 indexed citations

Liang, Jiaqi, Guoshu Bi, Xiaolong Huang, et al.. (2025). CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer. Cancer Communications. 45(11). 1547–1578.

Zhang, Mingyu, Jiayu Wang, Xi Chen, et al.. (2025). Nanofibers in Glioma Therapy: Advances, Applications, and Overcoming Challenges. International Journal of Nanomedicine. Volume 20. 4677–4703. 1 indexed citations

Xu, Zhijie, Tongfei Li, Qiaoli Yi, et al.. (2024). Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance. Drug Resistance Updates. 75. 101098–101098. 23 indexed citations

Chen, Xi, Yuanliang Yan, Yuanhong Liu, Qiaoli Yi, & Zhijie Xu. (2024). Tabersonine enhances cisplatin sensitivity by modulating Aurora kinase A and suppressing epithelial–mesenchymal transition in triple-negative breast cancer. Pharmaceutical Biology. 62(1). 394–403. 1 indexed citations

Zeng, Shuangshuang, et al.. (2024). CRABP2 reduces the sensitivity of Olaparib in ovarian cancer by downregulating Caspase-8 and decreasing the production of reactive oxygen species. Chemico-Biological Interactions. 393. 110958–110958.

Li, Yun, Zhijie Xu, Xiaofeng Huang, et al.. (2024). Application of Carbon Nanomaterials to Enhancing Tumor Immunotherapy: Current Advances and Prospects. International Journal of Nanomedicine. Volume 19. 10899–10915. 7 indexed citations

Peng, Bi, Jing Li, Yuanliang Yan, et al.. (2023). Non-coding RNAs: The recently accentuated molecules in the regulation of cell autophagy for ovarian cancer pathogenesis and therapeutic response. Frontiers in Pharmacology. 14. 1162045–1162045. 8 indexed citations

Lu, Can, Xi Chen, Yuanliang Yan, et al.. (2022). Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma. Frontiers in Pharmacology. 13. 768743–768743. 8 indexed citations

10.

Yan, Yuanliang, Yuan Cai, Qiuju Liang, et al.. (2022). Identification of m6A-Associated Gene DST as a Prognostic and Immune-Associated Biomarker in Breast Cancer Patients. SHILAP Revista de lepidopterología. 5 indexed citations

11.

Yi, Qiaoli, Jinwu Peng, Zhijie Xu, et al.. (2022). Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis. Frontiers in Bioengineering and Biotechnology. 10. 806851–806851. 9 indexed citations

12.

Xu, Zhijie, Bi Peng, Qiuju Liang, et al.. (2021). Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma. Frontiers in Immunology. 12. 719175–719175. 133 indexed citations

13.

Zhang, Zeyu, Yuanliang Yan, Yuan Cai, et al.. (2021). Evaluation of Ferroptosis-related Gene AKR1C1 as a Novel Biomarker Associated with the Immune Microenvironment and Prognosis in Breast Cancer. International Journal of General Medicine. Volume 14. 6189–6200. 23 indexed citations

14.

Xu, Zhijie, et al.. (2020). Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold. Journal of Cell Communication and Signaling. 14(1). 129–130. 2 indexed citations

15.

Yan, Yuanliang, Zhi Li, Shuangshuang Zeng, et al.. (2019). FGFR2-mediated phosphorylation of PTEN at tyrosine 240 contributes to the radioresistance of glioma. Journal of Cell Communication and Signaling. 13(3). 279–280. 13 indexed citations

16.

Zeng, Shuangshuang, Zhijie Xu, Xiang Wang, et al.. (2019). <p>Time series analysis of antibacterial usage and bacterial resistance in China: observations from a tertiary hospital from 2014 to 2018</p>. Infection and Drug Resistance. Volume 12. 2683–2691. 20 indexed citations

17.

Yan, Yuanliang, Zhijie Xu, Long Qian, et al.. (2019). Identification of CAV1 and DCN as potential predictive biomarkers for lung adenocarcinoma. American Journal of Physiology-Lung Cellular and Molecular Physiology. 316(4). L630–L643. 46 indexed citations

18.

Li, Zhi, Junju He, Shujun Fu, et al.. (2019). Epstein–Barr virus noncoding RNAs from the extracellular vesicles of nasopharyngeal carcinoma (NPC) cells promote angiogenesis via TLR3/RIG-I-mediated VCAM-1 expression. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1865(6). 1201–1213. 38 indexed citations

19.

Yan, Yuanliang, Weiping Su, Shuangshuang Zeng, et al.. (2018). Effect and Mechanism of Tanshinone I on the Radiosensitivity of Lung Cancer Cells. Molecular Pharmaceutics. 15(11). 4843–4853. 35 indexed citations

20.

Xu, Zhijie, Yuanliang Yan, Long Qian, & Zhicheng Gong. (2017). Long non-coding RNAs act as regulators of cell autophagy in diseases. Oncology Reports. 37(3). 1359–1366. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact